-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $124 Price Target

Benzinga·07/10/2026 12:34:30
Listen to the news
Guggenheim analyst Vamil Divan reiterates ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and maintains $124 price target.